CAMBRIDGE, Mass., June 7, 2018 – Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced the appointment of Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its Board of Directors.
“Jeff is an accomplished industry leader with deep scientific and business expertise and extensive experience in company building and in guiding early stage programs into clinical development,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “We are delighted to welcome him to our Board of Directors and look forward to drawing on his insights as we advance our GeneWave™ platform to create the first genetic medicines with drug-like properties.”
Dr. Jonas joined Sage as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the Sage team, Jeff served as president of the regenerative medicine division of Shire plc and previously as senior vice president of research and development, pharmaceuticals at Shire. Prior to Shire, he served as the executive vice president of ISIS Pharmaceuticals (now known as Ionis Pharmaceuticals), as the chief medical officer and executive vice president of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and president, and SCEPTOR Industries, where he served as chairman, president and chief technology officer. Earlier in his career, he served as independent director at Cara Therapeutics, Inc. and director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards. Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as chief resident in psychopharmacology at McLean Hospital, Harvard Medical School.
“Generation Bio has a therapeutic platform with the unique potential to deliver titratable, re-dosable genetic medicines,” said Dr. Jonas. “I am thrilled at this opportunity to join the effort to significantly advance the company’s mission to bring transformative medicines to patients with a range of genetic diseases.”
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWaveTM technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Ten Bridge Communications